Select Page

CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. On December 7, the application for Emergency Use Authorization (EUA) for the Revogene® SARS-CoV-2 assay was submitted to the U.S. Food and Drug Administration (FDA).